A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy

A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lianhai, Yang, Jie, Cai, Jie, Song, Xiaoming, Deng, Jianyun, Huang, Xuesong, Chen, Dawei, Yang, Mengmeng, Wery, Jean-Pierre, Li, Shuangxi, Wu, Aiwen, Li, Ziyu, Li, Zhongwu, Liu, Yiqiang, Chen, Yiyou, Li, Qixiang, Ji, Jiafu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801116/
https://www.ncbi.nlm.nih.gov/pubmed/24141978
http://dx.doi.org/10.1038/srep02992
Descripción
Sumario:A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.

Ejemplares similares